Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

Research output: Contribution to journalJournal articleResearchpeer-review

  • Nubia Muñoz
  • Susanne K Kjaer
  • Kristján Sigurdsson
  • Ole-Erik Iversen
  • Mauricio Hernandez-Avila
  • Cosette M Wheeler
  • Gonzalo Perez
  • Laura A Koutsky
  • Eng Hseon Tay
  • Patricía J Garcia
  • Kevin A Ault
  • Suzanne M Garland
  • Sepp Leodolter
  • Sven-Eric Olsson
  • Grace W K Tang
  • Daron G Ferris
  • Jorma Paavonen
  • Marc Steben
  • F Xavier Bosch
  • Joakim Dillner
  • Warner K Huh
  • Elmar A Joura
  • Robert J Kurman
  • Slawomir Majewski
  • Evan R Myers
  • Luisa L Villa
  • Frank J Taddeo
  • Christine Roberts
  • Amha Tadesse
  • Janine T Bryan
  • Lisa C Lupinacci
  • Katherine E D Giacoletti
  • Heather L Sings
  • Margaret K James
  • Teresa M Hesley
  • Eliav Barr
  • Richard M Haupt
The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were "negative to 14 HPV types" and in a mixed population of HPV-exposed and -unexposed women (intention-to-treat group).
Original languageEnglish
JournalNational Cancer Institute. Journal (Online)
Issue number5
Pages (from-to)325-39
Number of pages15
Publication statusPublished - 3 Mar 2010

ID: 34127886